Immediate versus delayed facilitated percutaneous coronary intervention: a pilot study

J Cardiovasc Pharmacol. 2005 Jul;46(1):83-8. doi: 10.1097/01.fjc.0000164089.96445.d8.

Abstract

The study was aimed to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI <2 hours, and in patients initially successfully treated with pharmacological therapy and delayed PCI (12-72 hours). All patients had to have successful reperfusion, to receive the combination of a standard abciximab infusion plus half dose rtPA. Similar results were observed in both groups. Delayed PCI group showed a favorable trend in restenosis and bleedings (ns) and a significant reduced angiographic evidence of thrombus formation in IRA. Our very preliminary data suggest the safety and possible use of delayed facilitated PCI in patients with STEMI. The studied patients have successful reperfusion and TIMI-3 flow and our data may not apply to patients with TIMI 0-2 flow.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Abciximab
  • Adult
  • Angioplasty, Balloon, Coronary / methods*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use
  • Electrocardiography
  • Eligibility Determination / methods
  • Female
  • Humans
  • Immunoglobulin Fab Fragments / administration & dosage
  • Immunoglobulin Fab Fragments / therapeutic use
  • Male
  • Middle Aged
  • Myocardial Infarction / mortality
  • Myocardial Infarction / therapy
  • Myocardial Ischemia / mortality
  • Myocardial Ischemia / therapy
  • Myocardial Reperfusion / methods
  • Patient Selection
  • Pilot Projects
  • Platelet Aggregation Inhibitors / therapeutic use
  • Survival Rate
  • Time Factors
  • Tissue Plasminogen Activator / administration & dosage
  • Tissue Plasminogen Activator / therapeutic use
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Tissue Plasminogen Activator
  • Abciximab